GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Wiley ; 2006
    In:  BJU International Vol. 97, No. 1 ( 2006-01), p. 146-148
    In: BJU International, Wiley, Vol. 97, No. 1 ( 2006-01), p. 146-148
    Type of Medium: Online Resource
    ISSN: 1464-4096 , 1464-410X
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2006
    detail.hit.zdb_id: 2019983-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Annals of Clinical and Translational Neurology, Wiley, Vol. 10, No. 4 ( 2023-04), p. 553-567
    Abstract: Amyloidosis due to the transthyretin Ser77Tyr mutation (ATTRS77Y) is a rare autosomal‐dominant disorder, characterized by carpal‐tunnel syndrome, poly‐ and autonomic‐neuropathy, and cardiomyopathy. However, related symptoms and signs are often nonspecific and confirmatory tests are required. We describe the age and frequency of early symptoms and diagnostic features among individuals of Jewish Yemenite descent in Israel. Methods Records of mutation carriers were retrospectively reviewed. ATTRS77Y diagnosis was defined by the presence of amyloid in tissue and/or amyloid‐related cardiomyopathy. Results We identified the Ser77Tyr mutation at the heterozygous state in 19 amyloidosis patients (mean age at diagnosis: 62 ± 5.7 years, range 49–70) and 30 amyloid‐negative carriers. The probability for disease diagnosis increased from 4.4% at age 49 to 100% at 70 and occurred earlier in males. Initial symptoms preceded diagnosis by 5 ± 3.8 years (range 0–12) and were commonly sensory changes in the extremities. Erectile dysfunction predated these in 8/13 (62%) males. In two patients cardiac preceded neurological symptoms. Two patients declined symptoms. Electrophysiological studies near the time of diagnosis indicated a median neuropathy at the wrist in 18/19 (95%) and polyneuropathy in 13/19 (68%). Skin biopsy revealed epidermal denervation in 15/16 (94%) patients. Cardiomyopathy was identified in 16/19 (84%). Sensory complaints or epidermal denervations were present in 17/30 (57%) of amyloid‐negative carriers and co‐occurred in 10/30 (33%). Interpretation ATTRS77Y symptoms commonly occur after age 50, but may begin earlier. Median neuropathy, skin denervation and cardiomyopathy are frequently identified. Symptoms may be absent in patients and common in amyloid‐negative carriers.
    Type of Medium: Online Resource
    ISSN: 2328-9503 , 2328-9503
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2740696-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Medicine, Wiley, Vol. 7, No. 11 ( 2018-11), p. 5470-5477
    Abstract: Current staging of pathological stage III colon cancer (CC) is suboptimal; many patients recur despite unremarkable preoperative staging. We previously reported that early postoperative PET‐CT can alter the stage and management of up to 15% of patients with high‐risk stage III CC. This study aimed to determine the role of the test in the general stage III CC population. Methods A retrospective study of all consecutive patients with stage III CC who underwent early postoperative PET‐CT between 2005 and 2017. Results A total of 342 patients, 166 (48.5%) males, median age 66 years (range, 29‐90), were included. Pathological stage was IIIA, IIIB, and IIIC in 18 (5.3%), 257 (75.1%), and 67 (19.6%) patients, respectively. Median number of positive lymph nodes was 2 (range, 0‐32). PET‐CT results modified the management of 46 patients (13.4%): 37 (10.8%) with overt metastatic disease and 9 (2.6%) with a second primary. The 5‐year disease‐free survival for true stage III patients was 81%. The median overall survival for the entire cohort and for true stage III patients was not reached and was 57.2 months for true stage IV. Of the 37 patients found to be metastatic, 14 (37.8%) underwent curative treatments and 9/14 (64.3%) remain disease‐free, with a median follow‐up of 83.8 months. Predictive factors for upstaging following PET‐CT were identified. Conclusion Early postoperative PET‐CT changed the staging and treatment of 13.4% of stage III CC patients and has the potential for early detection of curable metastatic disease. Outcome results are encouraging. Prospective validation is ongoing.
    Type of Medium: Online Resource
    ISSN: 2045-7634 , 2045-7634
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 2659751-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Alzheimer's & Dementia, Wiley, Vol. 18, No. S11 ( 2022-12)
    Abstract: Limited information exist regarding the reaction of cognitively unimpaired research participants to amyloid status disclosure and even more so in observational studies. We aimed to assess the associations of amyloid status disclosure with reported subjective memory concern, motivation to change lifestyle, anxiety, and depression. Method Research participants that take part in two observational studies and two clinical trials that incorporate amyloid‐PET where included. Participants received information regarding amyloid‐PET testing, results, and interpretation. They then performed an interview prior to PET scan and four‐to‐six‐month following result disclosure assessing their subjective memory concern, motivation to change lifestyle, anxiety, and depression from the possibility of a positive amyloid‐PET result. Result 130 cognitively normal adults completed both the pre‐PET and post‐PET questionnaires. Only 11 had a positive amyloid‐PET result and thus were excluded from the analyses. Of the 119 subjects with a negative PET scan, 70 (59%) were females, mean age = 62Y (rang 44‐88Y), mean education = 16Y (4‐25), mean MMSE = 29 (24‐30); most (64%) reported no memory concerns or mild memory concerns (1/2 on a scale of 5). This increased to 94% at 4‐6 month following amyloid‐PET disclosure ( Figure 1 ). Most (84%) had high or very high motivation to change lifestyle (4/5 in a scale of 5) in the pre‐PET assessment. This decreased to 30% in the post‐PET assessment. High and very high (4/5 in a scale of 5) anxiety and depression from a positive amyloid scan rates decreased from 25% to 0% and from 10% to 0%, respectively following a negative PET result disclosure ( Figure 1 ). Although most individuals reported favorable post‐PET changes, a few subjects experienced increase in memory decline (N = 8), anxiety (N = 6) or depression (N = 1) following disclosure ( Figure 2 ). Conclusion In cognitively normal adults, the disclosure of a negative amyloid‐PET scan result was associated with a general “comforting” effect as reflected by less subjective memory concerns, anxiety, and depression, and lower motivation to perform lifestyle changes. By AAIC 2022, we anticipate more participants who are amyloid‐PET positive allowing to compare their behavioral changes after disclosure of amyloid results to the changes of those who are amyloid‐PET negative.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Asia-Pacific Journal of Clinical Oncology, Wiley, Vol. 17, No. 2 ( 2021-04)
    Abstract: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment for advanced non‐small‐cell lung cancer (NSCLC), yet many patients do not benefit from Programmed cell death protein 1 (PD‐1) axis inhibitors, emphasizing the need for additional markers for better patient selection. Our aim was to evaluate the association between tumor volume and response to ICI. Methods This retrospective ethically‐approved study included all consecutive patients with advanced NSCLC who were evaluated with a fluorodeoxyglucose‐positron emission tomography scan, prior to the first administration of a single‐agent ICI between 1/2016 and 6/2017. Tumor burden was calculated based on total body metabolic tumor volume and sum of all measurable lesions (SOML). Results Median SOML was 88 mm, and was inversely and significantly associated with progression‐free survival (PFS) (hazard ratio [HR] 2, CI 1.28‐3.37, P  = .003) and overall survival (OS) (HR 2.36, CI 1.13‐4.94, P  = .02). SOML≤80 mm had a significantly longer PFS compared to patients with a SOML≥80 mm (median PFS 9.7 vs 3.7 months, respectively, HR for progression 2.26, CI 1.1‐4.5, P  = .02). Patients with a SOML≤80 also had longer median OS compared to patients with SOML≥80 (median OS 12 vs 9.8 months, respectively, HR for death 3.1, CI 1.2‐8, P  = .018). Conclusions Low tumor burden was associated with higher response rates (RR), and better PFS and OS in advanced NSCLC patients treated with ICI. These results may improve the selection of patients for treatment with single‐agent ICI, as opposed to the combination with chemotherapy, which might be more appropriate for patients with high tumor burden. Prospective analysis is warranted.
    Type of Medium: Online Resource
    ISSN: 1743-7555 , 1743-7563
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2187409-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Alzheimer's & Dementia, Wiley, Vol. 17, No. S4 ( 2021-12)
    Abstract: Various factors contribute to cognitive decline in older adults with type 2 diabetes (T2D). We assessed the association between imaging metrics of brain pathology (including global atrophy, small vessel disease, and amyloid deposition) with cognitive functioning in older adults with T2D. Method Community‐dwelling, cognitively normal, older adults with T2D from the Israel Diabetes and Cognitive Decline Study with brain MRI and/or F18‐Flutemetamol amyloid‐PET were included. Gray matter (GM) and white matter hyperintensities (WMH) volume were extracted from high‐resolution T1‐weighted and fluid‐attenuated inversion recovery (FLAIR), respectively, using Statistical Parametric Mapping (SPM8). Amyloid PET was visually read and quantified using standardized uptake value ratio (SUVR) with the cerebellar gray and white matter as reference region. Global mean and lobar SUVR were extracted. Global cognitive functioning was assessed by neuropsychological testing and summarized into four domains including executive functions, attention, memory, and language, and an average of the four domains comprised global cognition. Linear regression models were used in a stepwise manner controlling for age, sex, education, HbA1c, and duration of T2D. MRI measures were also adjusted for intracranial volume. Result 236 participants, 232 with MRI and 52 with amyloid‐PET were included, mean age 75 [66‐89], 39% females, 11 (21.1%) amyloid positive (Table 1). On average, participants had good glycemic control (mean HbA1C=6.7). An increase in global SUVR was associated with lower global cognition (Estimate=‐1.23, p=0.02). Additional adjustment for GM volume did not alter the results (Table 2). These results were driven by associations of SUVR with executive functioning (‐1.32, p=0.01), though a trend toward the same direction was also seen with attention (‐0.95, p=0.09), language (‐0.86, p=0.13), and memory (‐0.85, p=0.14) (Figure 1). Amyloid in all lobes contributed significantly to the associations (Table 2). No association was found between WMH volume and any of the cognitive outcomes (p‐values 〉 0.21). Conclusion In our cohort of normal cognitive older adults with well controlled T2D, amyloid load but not small vessel disease nor glycemic control was associated with cognitive functioning. This association was not mediated by GM volume suggesting other neurobiological substrates underlying the effect of amyloid on cognition in this population.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Wiley ; 2019
    In:  Otolaryngology–Head and Neck Surgery Vol. 160, No. 4 ( 2019-04), p. 729-733
    In: Otolaryngology–Head and Neck Surgery, Wiley, Vol. 160, No. 4 ( 2019-04), p. 729-733
    Abstract: Fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET‐CT) has been increasingly used in the past decade. Incidental FDG‐avid findings are encountered in these studies, several of which with clinical significance. However, the significance of incidental FDG‐avid sinonasal findings has not been studied to date. Study Design Retrospective cohort study. Setting A single tertiary medical center. Materials and Methods The medical records were reviewed of patients with incidental sinonasal positive FDG uptake between 2007 and 2016 who referred for further otolaryngological diagnostic workup. Results A total of 26 patients were identified, all of whom underwent a diagnostic surgical procedure. Histopathology revealed chronic inflammation (n = 12, 46.1%), malignancy (n = 7, 26.9%), inverted papilloma (n = 4, 15.5%), and fungal infections (n = 3, 11.5%). A unilateral maxillary sinus with FDG uptake was documented for 16 (61.5%) patients. CT evidence of bilateral disease and mucosal or sinus wall thickening correlated with inflammatory disease. Conclusions Incidental lesions with positive FDG uptake in the sinonasal cavities are at a high risk (40%) of being neoplastic. A diagnostic biopsy is advocated in these cases.
    Type of Medium: Online Resource
    ISSN: 0194-5998 , 1097-6817
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2008453-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Hematological Oncology, Wiley, Vol. 37, No. 2 ( 2019-04), p. 168-175
    Abstract: We evaluated the role of 18‐fluoro‐2‐deoxy‐ d ‐glucose positron emission tomography ( [18F] FDG‐PET) with computed tomography (CT) (PET/CT) as a diagnostic and prognostic tool in newly diagnosed marginal zone lymphoma (MZL) patients. This is a retrospective cohort study of patients with newly diagnosed MZL, treated with immunotherapy, chemotherapy regimens, surgery, or Helicobacter pylori eradication between 2008 and 2016 in a single tertiary center. Only patients who had a pretreatment PET/CT (P‐PET/CT) were included. P‐PET/CT, interim (I‐PET/CT), and end‐of‐treatment PET/CT (E‐PET/CT) studies were reviewed. P‐PET/CT results were reported using two methods of evaluation, qualitative and semi quantitative: visual assessment (VAS) and maximal standardized uptake value (SUVmax), and I‐PET and E‐PET results were reported by Deauville 5‐point score (DS) evaluation as well. Avidity of PET/CT was defined as abnormal uptake in any of these methods. The primary outcome was the prognostic role of P‐PET/CT, I‐PET/CT, and E‐PET/CT on progression‐free survival (PFS) and overall survival (OS). Data of 196 patients with MZL were identified, 110 of which had P‐PET/CT and were included in this analysis. Median age was 67 years (range 18‐93). The median follow‐up period was 63 months (range 3‐278). The median OS and PFS for the whole cohort were 63 (interquartile range 39‐85) and 60 (interquartile range 37‐76) months, respectively. The avidity of PET at baseline for the whole cohort was 70% (77/110 patients), for MALT lymphoma, 62.5% (40/64 patients), for NMZL, 76.4% (13/17 patients), and for SMZL, 82.7% (24/29 patients). When adjusted for IPI, sex, and comorbidities, positive E‐PET/CT was associated with reduced PFS with a hazard ratio (HR) of 3.4 (95% CI, 1.27‐9.14, P  = 0.02). Positive E‐PET/CT did not correlate with OS. However, there were only three events. P‐PET/CT was not predictive of PFS or OS. Our study demonstrates that above 70% of MZL are FDG avid. Positive E‐PET/CT is a strong prognostic factor for PFS.
    Type of Medium: Online Resource
    ISSN: 0278-0232 , 1099-1069
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2001443-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...